Form 4: Jazz Pharmaceuticals Executive Patricia Carr Reports Stock Sale

Patricia Carr, SVP and Chief Accounting Officer at Jazz Pharmaceuticals, sold 53 ordinary shares on December 2, 2024.

Summary

• Patricia Carr, a Senior Vice President and Chief Accounting Officer at Jazz Pharmaceuticals, reported a sale of 53 ordinary shares.
• The transaction occurred on December 2, 2024, at a price of $122.49 per share.
• The shares were sold under a Section 423 Employee Stock Purchase Plan.
• Following the transaction, Ms. Carr directly owns 6,596 ordinary shares.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale, which is neither positive nor negative for the company's overall performance.

Industry Context

This is a routine disclosure of an insider transaction, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for executives participating in employee stock purchase plans.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small sale by an executive.

Key Dates

Keywords

Jazz Pharmaceuticals, insider trading, stock sale, Patricia Carr, Section 423 Employee Stock Purchase Plan, JAZZ